Payment overview · 2025
General Payments
$475.94
23 reported records · 10 companies
Healthcare provider profile · identity verified
Teri Lyn Roberts, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MOREHEAD, KY · NPI 1891780193
Verified facts
What the public records show
CMS Open Payments records show Teri Lyn Roberts, APRN received $475.94 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $121.07 | 25.4% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.82 | 14.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $65.49 | 13.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.34 | 13.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $61.08 | 12.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.68 | 5.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.81 | 4.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.55 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.89 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.21 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $475.94 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $101.99 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $69.82 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $65.49 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $63.34 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $61.08 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 392 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 272 | 86 |
| Omeprazole | Omeprazole | 241 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 240 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 69 |
| Gabapentin | Gabapentin | 198 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 60 |
| Famotidine | Famotidine | 166 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 54 |
| Losartan Potassium | Losartan Potassium | 158 | 46 |
| Metformin Hcl | Metformin Hcl | 147 | 40 |
| Trazodone Hcl | Trazodone Hcl | 139 | 41 |
| Buspirone Hcl | Buspirone Hcl | 130 | 35 |
| Potassium Chloride | Potassium Chloride | 126 | 33 |
| Furosemide | Furosemide | 119 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 39 |
| Ozempic | Semaglutide | 119 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 40 |
| Tramadol Hcl | Tramadol Hcl | 94 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 23 |
| Montelukast Sodium | Montelukast Sodium | 87 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 27 |
| Simvastatin | Simvastatin | 80 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 21 |
| Sertraline Hcl | Sertraline Hcl | 71 | 25 |
| Trulicity | Dulaglutide | 70 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 69 | 29 |
| Januvia | Sitagliptin Phosphate | 67 | 19 |
| Meloxicam | Meloxicam | 66 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 18 |
| Carvedilol | Carvedilol | 63 | 19 |
| Jardiance | Empagliflozin | 63 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 20 |
| Prednisone | Prednisone | 60 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 19 |
| Eliquis | Apixaban | 54 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 18 |
| Farxiga | Dapagliflozin Propanediol | 52 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 19 |
| Atenolol | Atenolol | 47 | 14 |
| Spironolactone | Spironolactone | 47 | 16 |
| Allopurinol | Allopurinol | 46 | 15 |
| Clonidine Hcl | Clonidine Hcl | 45 | 13 |
| Ezetimibe | Ezetimibe | 43 | 12 |
| Ibuprofen | Ibuprofen | 43 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 35 |
| Nystatin | Nystatin | 40 | 11 |
| Glipizide Er | Glipizide | 39 | 11 |
| Cephalexin | Cephalexin | 38 | 17 |
| Naproxen | Naproxen | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 33 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Nabumetone | Nabumetone | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 11 |
| Ondansetron Odt | Ondansetron | 27 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Cefdinir | Cefdinir | 26 | 25 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 19 |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 11 |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dapsone | Dapsone | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Epinephrine | Epinephrine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $475.94 · 23 records | ABBVIE INC. | Auvelity, CAPLYTA, Dexcom G6 Transmitter, FARXIGA, Fabhalta, JARDIANCE, MAVYRET, REXULTI, VOQUEZNA, VRAYLAR, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error